Searched for
LILLY INTERNATIONAL
Centre set to tighten oversight of pharma packaging materialsIndia is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This mov...- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- DeepMind CEO Demis Hassabis’ Isomorphic Labs raises $2.1 billion led by Thrive CapitalAI-driven drug discovery firm Isomorphic Labs secured a massive $2.1 billion in Series B funding. This capital will fuel the expansion of t...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- Different packaging, typos expose fake Mounjaro racketGurugram authorities uncovered a counterfeit Mounjaro operation. Police seized fake diabetes and weight loss injections valued at ₹70 lakh....
- India is well positioned to attract future investments, says Eli Lilly's Patrik JonssonEli Lilly's Patrik Jonsson urges India to accelerate regulatory review pathways to boost competitiveness, emphasizing the need for data pro...
- India is well positioned to attract future investments: Patrik Jonsson, President, Lilly InternationalEli Lilly's Patrik Jonsson urges India to accelerate regulatory review pathways to boost competitiveness, emphasizing the need for stronger...
- LLY stock jumps 9%: Why Eli Lilly stock is soaring today - Mounjaro, Zepbound sales drive massive earnings beat and 2026 forecast stuns Wall StreetLLY stock today: Eli Lilly's stock saw a significant jump following impressive fourth-quarter results and a strong 2026 financial forecast....
- Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatmentEli Lilly's diabetes drug Mounjaro will be added to China's state health insurance from January 1, making it more accessible to the country...
- Cipla to sell Lilly's weight-loss drug in IndiaEli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under ...
- Eli Lilly's obesity drug Mounjaro's India sales hit a sweet spot within six months of launchLilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within ...
- Eli Lilly to invest $1 billion in India, expand manufacturing and introduce oral weight-loss drugEli Lilly is significantly expanding its Indian operations with over $1 billion in contract manufacturing investments and plans for a globa...
- Eli Lilly to invest over $1 billion in India to expand manufacturing capacityEli Lilly will invest over $1 billion in India to boost manufacturing and supply through local drugmakers, increasing the availability of k...
- After Mounjaro Jab, Eli Lilly plans weight loss pill launch in IndiaEli Lilly plans to launch an oral weight loss drug, orforglipron, after Mounjaro's India success. Regulatory submissions are expected soon,...
- Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demandEli Lilly's Mounjaro has seen a positive reception in India, capturing significant sales and market interest since its launch in March. The...
- Twitter prank spurs unexpected scrutiny of insulin pricesAmong the victims was drugmaker Eli Lilly, whose stock price nosedived -- erasing billions in market capitalization -- after a parody accou...
- Eli Lilly Q3 net rises 10% $874mEli Lilly said on Thursday that its profit rose 10% during the third quarter on modest growth by its best-selling drug, the antipsychotic Z...
Load More
